Naoko Okino

Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction

Sadayoshi Ito, Minoru Satoh, Yuko Tamaki et al. · Hypertension Research · 2015 · 105 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study

Hiroyuki Tsutsui, Shin‐ichi Momomura, Yoshihiko Saito et al. · Journal of Cardiology · 2016 · 50 citations

Medicine, Cardiology, Pharmacology +17

<scp>LCZ</scp>696, a First‐in‐Class Angiotensin Receptor‐Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension

Kazuomi Kario, Yuko Tamaki, Naoko Okino et al. · Journal of Clinical Hypertension · 2015 · 47 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: A 12‐week, placebo‐controlled study

Masaharu Kinoshita, Sang Haak Lee, Liang‐Wen Hang et al. · Respirology · 2011 · 41 citations

Medicine, Internal Medicine, Pharmacotherapy +17

Angiotensin Receptor Neprilysin Inhibitor in Japanese Patients With Heart Failure and Reduced Ejection Fraction　― Baseline Characteristics and Treatment of PARALLEL-HF Trial ―

Hiroyuki Tsutsui, Shin-ichi Momomura, Yoshihiko Saito et al. · Circulation Journal · 2018 · 20 citations · Full text

Medicine, Cardiology, Pharmacology +16